Position
Renaissance Technologies in BridgeBio Pharma, Inc.
Back to the book · All holders of BBIO
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $80.5K$74.26 → $74.48
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q1 2026 | 365.8K | $27.2M | — | — | — | 0.0% |
| Q2 2026 | 856.8K | $63.8M | $74.48 | $80.5K | $36.6M | 0.1% |